Avadel Pharmaceuticals plc(AVDL)

Search documents
Avadel Pharmaceuticals plc(AVDL) - 2023 Q2 - Quarterly Report
2023-08-08 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37977 ——————— AVADEL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) ——————— Ireland 98-1341933 ...
Avadel Pharmaceuticals (AVDL) Update / Briefing Transcript
2023-06-29 14:00
Avadel Pharmaceuticals (AVDL) Update / Briefing June 29, 2023 09:00 AM ET Speaker0 First of all, thank you for everyone here in person and those on the webcast for joining us today for our Loomrise commercial day. We really appreciate you taking a few hours out of your Thursday morning to come and listen to a lot of the insights that we've we've gathered and garnered over the last couple of years as we frame out the early launch period and how we think about this unique opportunity. So before we get started ...
Avadel Pharmaceuticals (AVDL) Investor Presentation - Slideshow
2023-05-18 16:25
Avadel Pharmaceuticals plc (NASDAQ: AVDL) May 2023 ©2023 Avadel. All rights reserved. Safe Harbor Statements This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. Such forward-looking statements include, but a ...
Avadel Pharmaceuticals plc(AVDL) - 2023 Q1 - Quarterly Report
2023-05-03 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37977 ——————— AVADEL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) ——————— Ireland 98-134193 ...
Avadel Pharmaceuticals plc(AVDL) - 2022 Q4 - Earnings Call Transcript
2023-04-01 01:25
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Austin Murtagh – Stern Investor Relations Greg Divis – Chief Executive Officer Jennifer Gudeman – Senior Vice President-Medical and Clinical Affairs Richard Kim – Chief Commercial Officer Tom McHugh – Chief Financial Officer Conference Call Participants Chris Howerton – Jefferies Adam Evertts – LifeSci Capital David Amsellem – Piper Sandler Matt Kaplan – Ladenburg Thalmann Operator Greeti ...
Avadel Pharmaceuticals plc(AVDL) - 2022 Q4 - Annual Report
2023-03-28 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ____________ to ____________ Commission file number: 001-37977 AVADEL PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) Ireland 98-1341933 Registrant's te ...
Avadel Pharmaceuticals plc(AVDL) - 2022 Q3 - Earnings Call Transcript
2022-11-09 18:54
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Officer Tom McHugh - Senior Vice President & Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Ami Fadia - Needham Chris Howerton - Jefferies Adam Evertts - LifeSci Capital Marc Goodman - SVB Matt Kaplan - Ladenburg Th ...
Avadel Pharmaceuticals plc(AVDL) - 2022 Q1 - Earnings Call Transcript
2022-05-09 18:58
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Brandi Robinson - Senior Vice President of Corporate Affairs Douglas Williamson - Chief Medical Officer Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Officer Tom McHugh - Senior Vice President & Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Marc Goodman - SVB Secur ...
Avadel Pharmaceuticals plc(AVDL) - 2021 Q4 - Earnings Call Transcript
2022-03-17 22:33
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2021 Earnings Conference Call March 17, 2022 8:30 AM ET Company Participants Brandi Robinson - Senior Vice President, Corporate Affairs Gregory Divis - Chief Executive Officer Douglas Williamson - Chief Medical Officer Tom McHugh - Chief Financial Officer Richard Kim - Chief Commercial Officer Conference Call Participants Christopher Howerton - Jefferies David Amsellem - Piper Sandler & Co. Ami Fadia - Needham & Co. Paul Matteis - Stifel Oren Livnat - H.C. Wainwri ...
Avadel Pharmaceuticals plc(AVDL) - 2021 Q3 - Earnings Call Transcript
2021-11-08 18:53
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2021 Earnings Conference Call November 8, 2021 8:30 AM ET Company Participants Courtney Turiano - Investor Relations Gregory Divis - Chief Executive Officer Tom McHugh - Chief Financial Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Vice President of Medical and Clinical Affairs Conference Call Participants Christopher Howerton - Jefferies Francois Brisebois - Oppenheimer & Co. Inc. Ami Fadia - Needham & Co. Rudy Li - SVB Leerink David Amsellem ...